A Phase I Pharmacodynamic Study of Copanlisib (BAY 80-6946) as Monotherapy in Patients With Non-Hodgkin's Lymphoma and Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Copanlisib (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Pharmacodynamics
- Sponsors Bayer
- 07 Dec 2017 According to a Bayer media release, data from the study will be presented at the 59th Annual Meeting of the American Society of Hematology (ASH).
- 10 Jun 2017 Biomarkers information updated
- 06 Apr 2017 Status changed from active, no longer recruiting to completed.